Ellevest Inc’s Recursion Pharmaceuticals RXRX Stock Holding History

Ellevest Inc’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-19	Closed	–	–	1647
2022 Q1	$0	Buy	+19	New	+$202	﹤0.01%	1605

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OMS

Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DOFI

DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ellevest Inc's RXRX Position: Q2 2022 in Review

Ellevest Inc sold out of Recursion Pharmaceuticals (RXRX) in Q2 2022, closing a stake of 19 shares.

Ellevest Inc first reported a position in RXRX in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 133 funds tracked by Wall St. Rank hold RXRX as of Q2 2022.

Ellevest Inc reported no remaining Recursion Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Ellevest Inc sold 19 Recursion Pharmaceuticals shares in Q2 2022.
Ellevest Inc first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Ellevest Inc's Recursion Pharmaceuticals position peaked at $0 in Q1 2022.
133 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2022.

Based on Ellevest Inc's 13F filing for Q2 2022, filed 18 Jul 2022.